Literature DB >> 12727023

Downregulation of NF-kappaB activation in human keratinocytes by melanogenic inhibitors.

Kwang Seok Ahn1, Ki-Young Moon, Jinseon Lee, Yeong Shik Kim.   

Abstract

BACKGROUND: Exposure of skin cells, particularly keratinocytes to various nuclear factor-kappaB (NF-kappaB) activators (e.g. tumor necrosis factor-alpha, interleukin-1, lipopolysaccharides, and ultraviolet light) leads to phosphorylation and degradation of the inhibitory protein, IkappaB. Liberated NF-kappaB is translocated into the nucleus where it can change or alter expression of target genes, resulting in the secretion of extracellular signaling molecules including melanotrophic factors affecting melanocyte.
OBJECTIVE: In order to demonstrate the possible role of NF-kappaB activation on the synthesis of melanotrophic factors from the keratinocytes, the activities of NF-kappaB induced by melanogenic inhibitors (MIs) were determined in human HaCaT keratinocytes transfected with pNF-kappaB-SEAP-NPT plasmid. Transfectant cells released the secretory alkaline phosphatase (SEAP) as a transcription reporter in response to the NF-kappaB activity and contain the neomycin phosphotransferase (NPT) gene for the dominant selection marker for geneticin resistance.
METHODS: MIs such as niacinamide, kojic acid, hydroquinone, resorcinol, arbutin, and glycolic acid were preincubated with transfectant HaCaT cells for 3 h and then ultraviolet B (UVB) was irradiated. NF-kappaB activation was measured with the SEAP reporter gene assay using a fluorescence detection method.
RESULTS: Of the MIs tested, kojic acid (IC(50)=60 microM) was found to be the most potent inhibitor of UVB-upregulating NF-kappaB activation in transfectant HaCaT cells, which is followed by niacinamide (IC(50)=540 microM). Pretreatment of the transfectant HaCaT cells with the MIs, especially kojic acid and niacinamide, effectively lowered NF-kappaB binding measured by electrophoretic mobility shift assay. Furthermore, these two inhibitors remarkably reduced the secretion level of IL-6, one of melanotrophic factors, triggered by UV-radiation of the HaCaT cells.
CONCLUSION: These observations suggest that MIs working at the in vivo level might act partially through the modulation of the synthesis of melanotrophic factors in keratinocyte.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727023     DOI: 10.1016/s0923-1811(03)00039-2

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

1.  Morphologically dissimilar spores of Aspergillus sojae exhibit genomic homogeneity but the differential in Kojic acid accumulation.

Authors:  Vijay Lakshmi Jamwal; Shifali Chib; Vinod Kumar; Sumit G Gandhi; Saurabh Saran
Journal:  3 Biotech       Date:  2022-08-01       Impact factor: 2.893

2.  Targeting ALDH1A1 to treat pigmentary disorders.

Authors:  Konrad Kleszczynski; Andrzej T Slominski
Journal:  Exp Dermatol       Date:  2013-05       Impact factor: 3.960

3.  9-cis retinoic acid is the ALDH1A1 product that stimulates melanogenesis.

Authors:  Elyse K Paterson; Hsiang Ho; Rubina Kapadia; Anand K Ganesan
Journal:  Exp Dermatol       Date:  2013-03       Impact factor: 3.960

Review 4.  Burn injury induces elevated inflammatory traffic: the role of NF-κB.

Authors:  Benu George; T V Suchithra; Nitish Bhatia
Journal:  Inflamm Res       Date:  2020-11-27       Impact factor: 4.575

5.  Anti-inflammatory Effect of Isaria sinclairii Glycosaminoglycan in an Adjuvant-treated Arthritis Rat Model.

Authors:  Mi Young Ahn; Sang Duck Jee; Jae Sam Hwang; Eun Young Yun; Kwang Seok Ahn; Yeong Shik Kim
Journal:  Toxicol Res       Date:  2013-09

6.  Superior even skin tone and anti-ageing benefit of a combination of 4-hexylresorcinol and niacinamide.

Authors:  Rezwan Shariff; Yaping Du; Maitreyee Dutta; Satish Kumar; Sreenivasa Thimmaiah; Chandraprabha Doraiswamy; Annu Kumari; Vaidehi Kale; Nirmala Nair; Shuliang Zhang; Manoj Joshi; Uma Santhanam; Qiu Qiang; Anita Damodaran
Journal:  Int J Cosmet Sci       Date:  2022-02-01       Impact factor: 2.416

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.